Skip to main content
. 2025 Aug 12;16:1629473. doi: 10.3389/fimmu.2025.1629473

Figure 4.

Line graphs show anti-spike IgG avidity changes over 1 and 6 months post-vaccination for different groups, comparing two to four doses. Groups include Healthy Control, Multiple Myeloma, non-MM hematological, and Solid, with each category depicted in separate panels. Median avidity changes, percentiles, sample sizes, and p-values are provided, highlighting statistical significance where applicable.

Percent change in anti-spike IgG avidity from 1 month to 6 months post vaccination in cancer and healthy cohorts. Comparison of percent change in serum anti-spike IgG avidity between 1 month and 6 months post-vaccination in individuals receiving 2 doses (A), 3 doses (B) and 4 doses (C) of vaccine in healthy, multiple myeloma, non-MM hematological cancer and solid cancer cohorts. Percent change results were reported as Median with the first and third quartiles (Q1 and Q3). The p values indicate the significance levels of the percent change between 1 month and 6 months in the cancer cohort, compared to the percent change observed in the healthy cohort with the corresponding doses. Solid red line represents the connecting line of geometric mean titer at 1 month and 6 months in each cohort. Differences assessed by non-parametric Wilcoxon rank sum test.